medigraphic.com
ISSN 2007-6800 (Impreso)

2020, Número S1

<< Anterior Siguiente >>

Rev Mex Traspl 2020; 9 (S1)


Evaluación de la función renal del donante: TFG, proteinuria, hematuria y urolitiasis. ¿Cómo evaluar? ¿Quién puede donar?

Villca-Gonzáles R

Idioma: Español
Referencias bibliográficas: 56
Paginas: 22-29
Archivo PDF: 208.09 Kb.


FRAGMENTO

El nivel de la tasa de filtración glomerular (TFG) es ampliamente aceptada como el mejor índice general de la función renal en salud y en enfermedad. En la población general la disminución de la TFG está asociada con un mayor riesgo de falla renal crónica, enfermedad cardiovascular y muerte.
La TFG normal es aproximadamente de 130 mL/min/1.73 m2 en hombres y 120 mL/min/1.73 m2 en mujeres hasta los 25 años, con considerable variación entre individuos de acuerdo con la edad, sexo, tamaño corporal, entre otros. Para estandarizar la TFG se debe realizar el ajuste al área de superficie corporal. Posterior a los 40 años la tasa promedio de disminución de la TFG es aproximadamente 0.75 mL/min/año, existe una variabilidad amplia y las fuentes de esta variación todavía no están del todo establecidas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Inker LA, Levey AS. Assessment of glomerular filtration rate. In: Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. Elsevier; 2019. pp. 29-38.

  2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375 (9731): 2073-2081.

  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 1-150.

  4. Inker LA, Huang N, Levey AS. Strategies for assessing GFR and albuminuria in the living kidney donor evaluation. Curr Transplant Rep. 2017; 4 (1): 13-23.

  5. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009; 20 (11): 2305-2313.

  6. Soveri I, Berg UB, Bjork J, Elinder CG, Grubb A, Mejare I et al. Measuring GFR: a systematic review. Am J Kidney Dis. 2014; 64 (3): 411-424.

  7. Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006; 52 (1): 5-18.

  8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150 (9): 604-612.

  9. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156 (11): 785-795.

  10. Keddis MT, Amer H, Voskoboev N et al. Creatinine-based and cystatin C-based GFR estimating equations and their non-GFR determinants in kidney transplant recipients. Clin J Am Soc. 2016; 11 (9): 1640-1649.

  11. Eckfeldt JH, Karger AB, Miller WG, Rynders GP, Inker LA. Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS survey. Arch Pathol Lab Med. 2015; 139 (7): 888-893.

  12. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367 (1): 20-29.

  13. Fan L, Inker LA, Rossert J, Froissart M, Rossing P, Mauer M et al. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrol Dial Transplant. 2014; 29 (6): 1195-1203.

  14. Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101 (8S Suppl 1): S1-S109.

  15. Andrews PA, Burnapp L. British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018: Summary of Updated Guidance. Transplantation. 2018; 102 (7): e307.

  16. Delmonico F, Council of the Transplantation Society. A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005; 79: S53-S66.

  17. European Renal Best Practice Transplantation Guideline Development Group. ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant. 2013; 28 (Suppl. 2): ii1-ii71.

  18. OPTN/UNOS. Organ Procurement & Transplantation Network Policy 14: living donation. OPTN. 2016. Disponible en: https://optn.transplant.hrsa.gov/media/1200/optn_policies. pdf

  19. Huang N, Foster MC, Lentine KL, Garg AX, Poggio ED, Kasiske BL et al. Estimated GFR for Living Kidney Donor Evaluation. Am J Transplant. 2016; 16 (1): 171-180.

  20. Gaillard F, Flamant M, Lemoine S, Baron S, Timsit MO, Eladari D et al. Estimated or measured GFR in living kidney donors work-up? Am J Transplant. 2016; 16 (10): 3024-3032.

  21. Garg AX, Muirhead N, Knoll G, Yang RC, Prasad GV, Thiessen-Philbrook H et al. Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression. Kidney Int. 2006; 70 (10): 1801-1810.

  22. Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015; 66 (1): 114-124.

  23. Fehrman-Ekholm I, Nordén G, Lennerling A, Rizell M, Mjörnstedt L, Wramner L et al. Incidence of end-stage renal disease among live kidney donors. Transplantation. 2006; 82 (12): 1646-1648.

  24. Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H et al. Long-term consequences of kidney donation. N Engl J Med. 2009; 360 (5): 459-469.

  25. Cherikh WS, Young CJ, Kramer BF, Taranto SE, Randall HB, Fan PY. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant. 2011; 11 (8): 1650-1655.

  26. Mjøen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Øyen O et al. Long-term risks for kidney donors. Kidney Int. 2014; 86 (1): 162-167.

  27. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright J et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014; 311 (6): 579-586.

  28. Rizvi SA, Zafar MN, Jawad F, Aziz T, Hussain Z, Hashmi A et al. Long-term Safety of Living Kidney Donation in an Emerging Economy. Transplantation. 2016; 100 (6): 1284-1293.

  29. Fogazzi GB, Garigali G. Urinalysis. In: Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. Elsevier; 2019. pp. 39-52.

  30. Inker LA. Albuminuria: time to focus on accuracy. Am J Kidney Dis. 2014; 63 (3): 378-381.

  31. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl. 2005; (94): S28-S35.

  32. Grams ME, Sang Y, Levey AS et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl JMed. 2016; 374: 411-421.

  33. Mandelbrot DA, Pavlakis M, Danovitch GM et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant. 2007; 7: 2333-2343.

  34. Davis R, Jones JS, Barocas DA et al. American Urological Association (AUA) guideline ADULTS: AUA guideline American Urological Association asymptomatic microhematuria. J Urol. 2012; 188 (6 Suppl): 2473-2481.

  35. Kassouf W, Aprikian A, Black P et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J. 2016; 10: E46-E80.

  36. Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med. 2003; 348: 2330-2338.

  37. Shen P, He L, Jiang Y, Wang C, Chen M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria. Int J Clin Pract. 2007; 61 (5): 789-794.

  38. Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care. BMJ. 2009; 338: a3021.

  39. Hole B, Whittlestone T, Tomson C. Investigating asymptomatic invisible haematuria. BMJ. 2014; 349: g6768.

  40. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24 (3): 179-196.

  41. Savige J, Rana K, Tonna S et al. Thin basement membrane nephropathy. Kidney Int. 2003; 64: 1169-1178.

  42. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol. 2012; 62: 160-165.

  43. Boyce CJ, Pickhardt PJ, Lawrence EM, Kim DH, Bruce RJ. Prevalence of urolithiasis in asymptomatic adults: objective determination using low dose non contrast computerized tomography. J Urol. 2010; 183 (3): 1017-1021.

  44. Lorenz EC, Lieske JC, Vrtiska TJ et al. Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant. 2011; 26: 2695-2700.

  45. Olsburgh J, Thomas K, Wong K et al. Incidental renal stones in potential live kidney donors: prevalence, assessment and donation, including role of ex vivo ureteroscopy. BJU Int. 2013; 111 (5): 784-792.

  46. O’Neill DC, Davis NF, Murray TÉ, Lee MJ, Little D, Morrin MM. Prevalence of incidental findings on multidetector computed tomography in potential nephrectomy donors: a prospective observational study. Exp Clin Transplant. 2019; 17 (2): 177-182.

  47. Kim IK, Tan JC, Lapasia J, Elihu A, Busque S, Melcher ML. Incidental kidney stones: a single center experience with kidney donor selection. Clin Transplant. 2012; 26 (4): 558-563.

  48. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010; 25: 831-841.

  49. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004; 44: 799-805.

  50. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney stones and kidney function loss: a cohort study. BMJ. 2012; 345: e5287.

  51. El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd et al. Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol. 2012; 7 (9): 1409-1415.

  52. Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A et al. The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol. 2017; 198 (2): 268-273.

  53. Pearle MS, Goldfarb DS, Assimos DG et al. Medical management of kidney stones: AUA guideline. J Urol. 2014; 192: 316-324.

  54. Serur D, Charlton M, Juluru K et al. Long term follow up of kidney donors with asymptomatic renal stones. Nephrology. 2017; 22: 649-651.

  55. Sarier M, Duman I, Callioglu M, Soylu A, Tekin S, Turan E et al. Outcomes of conservative management of asymptomatic live donor kidney stones. Urology. 2018; 118: 43-46.

  56. Sarier M, Duman I, Yuksel Y, Tekin S, Ozer M, Yucetin L et al. Ex vivo stone surgery in donor kidneys at renal transplantation. Int J Urol. 2018; 25 (10): 844-847.




2020     |     www.medigraphic.com